Français Néerlandais Japonais Chinois Allemand Espagnol Portugais

Worldwide innovation—Cousin Biotech develops pain-relieving implant

03 Oct 2017 | Front page, Advanced Materials, A region on the move

Cousin Biotech, a specialist in technical textiles for medical applications based in Hauts-de-France, has developed an implant that can replace oral pain medication after inguinal hernia surgery.

textiles, medical, innovation

Worldwide first

After seven years of research and development, Cousin Biotech has created an innovative implant that can replace oral pain medication in patients with inguinal hernias. Analgesic compounds are grafted onto the fabric of the implant, which is placed directly on the painful area after surgery and diffuses painkillers into the body. In 12% of patients, the implant is expected to outperform pills in managing post-operative pain.

There are already implants for this type of operation, but none of them can release painkillers into the body after surgery,” says CEO François Tortel.

Successful differentiation strategy

Based in Wervicq-Sud, Cousin Frères Group has made innovation a watchword. In 1989 the company embraced the trend toward medical applications for technical textiles, then founded Cousin Biotech in 1995 to adapt its expertise for new markets.

To compete successfully with major international players in the industry, Cousin Biotech has focused on making the surgeon’s job easier and improving quality of life for patients.

Major market potential

Cousin Biotech does business in 61 countries and sells over 400 different medical products: every three minutes, a Cousin Biotech implant is placed somewhere around the world.

With this latest innovation, the company is targeting major international markets. Some 2 million inguinal hernia operations are performed annually, including 140,000 in France.

In two years, Cousin Biotech will have the necessary regulatory approvals from the European Union, and can begin marketing its implant, first in Europe and then worldwide.

 

Source: CCI Nord de France, Cousin Biotech

Back to news

News

Verescence: a €60M investment in Hauts-de-France

London-based Stirling Square acquired a stake in the company at the start of the year, invest-ing €122M in the Verescence 2022 project. €60M of this is destined for its historic Mers-les-Bains site in...

Hauts-de-France a winner in first ever Choose France Awards

Hauts-de-France won the prize for “regional attractiveness” at the first ever Choose France Awards, organised by Business France in Paris, on November 21.

All news